2025 Universal Registration Document
Presentations, Reports & Regulated information
Get all the information you need about our results and future outlook.
10/28/2022 - 2022 Half-year results (Presentation)
10/20/2022 - Revenue on September 30, 2022
10/07/2022 - Half-year financial report 2022
09/26/2022 - Guerbet obtains one million euros of public funding from Bpifrance for a project developing AI for the early detection of pancreatic cancer
09/21/2022 - Guerbet Announces U.S. Food And Drug Administration (FDA) Approval Of Eluciremtm
09/21/2022 - 2022 Half Year Results
07/21/2022 - H1 2022 Sales
06/13/2022 - Guerbet receives EMA acceptance of Elucirem™ as the Brand Name for Gadopiclenol
Legal mentions
This website contains data provided by Euronext. Such data is for information purposes only and is not a recommendation to engage in investment activities. Such data is provided “as is” without representation or warranty of any kind. Whilst all reasonable care has been taken to ensure the accuracy of the data, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on data provided. No Euronext data shall form the basis of any contract. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with such data shall vest in Euronext. No part of it may be redistributed or reproduced in any form without the prior written permission of Euronext. Euronext does not control the content of this website and does not guarantee the accuracy, integrity or quality of such content and under no circumstances will Euronext be liable in any way for such content. Euronext refers to Euronext N.V. and its affiliates.